Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04272463
Other study ID # D3250R00073
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 13, 2020
Est. completion date July 15, 2020

Study information

Verified date August 2023
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational, Italian multi-center, retrospective cohort study with enrollment visit on patients suffering from severe eosinophilic asthma who started benralizumab in the Sampling Program or as per normal clinical practice in Italy.


Description:

A retrospective cohort study design involving secondary data collection was chosen to appropriately address the primary objective in a relatively short period of time after enrollment phase initiation: in fact, since the Italian Sampling Program on benralizumab was active since July 2018, clinical data on patients exposed to benralizumab are already available. No treatments will be administered per protocol requirement, but instead according to normal clinical practice; since benralizumab first administration occurs before inclusion in the study (as per chosen study design), the decision to include the patient in the study is clearly separated from the prescription of benralizumab, in accordance with the observational nature of the study. In order to be eligible for the study, for each patient, the index date shall be at least 3 months prior to enrollment.


Recruitment information / eligibility

Status Completed
Enrollment 217
Est. completion date July 15, 2020
Est. primary completion date July 15, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Adult patients (age =18 years) at the start of benralizumab treatment within the sampling program or per clinical practice ("index date"). 2. Patients with severe eosinophilic asthma requiring a stable treatment of high doses of inhaled corticosteroids and a long acting ß2 agonist ± additional asthma controller (according to clinician's judgment). 3. Patients who started benralizumab and received at least one injection at least 3 months before enrollment, either within the sampling program or as per routine clinical practice. 4. Patients who signed the informed consent and privacy form at enrollment visit. 5. Patients with available hospital medical chart since the start of benralizumab treatment within the sampling program or per clinical practice ("index date"). Exclusion Criteria: 1. Patients who, during the observation period, received benralizumab in a clinical experimental trial. 2. Patients who, during the observation period, participated in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
No intervention
Patients currently in treatment with benralizumab as per approved indication and clinical practice

Locations

Country Name City State
Italy Research Site Acquaviva delle Fonti
Italy Research Site Bergamo
Italy Research Site Cassano Murge
Italy Research Site Catanzaro
Italy Research Site Firenze
Italy Research Site Foggia
Italy Research Site Garbagnate Milanese
Italy Research Site Milano
Italy Research Site Monserrato
Italy Research Site Napoli
Italy Research Site Ostuni
Italy Research Site Reggio Emilia
Italy Research Site Roma
Italy Research Site Rozzano
Italy Research Site Siena
Italy Research Site Torino
Italy Research Site Treviso
Italy Research Site Verona

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary key features at benralizumab treatment start) Total IgE and eosinophils count in peripheral blood as measured at index date Lung function assessments Presence of comorbidities Previous severe exacerbations in the 12 months before index date. Previous treatments with biologics for asthma before index date. Maintenance asthma treatment(s) ongoing at index date. At baseline
Secondary severe exacerbations during benralizumab treatment Proportion of patients experiencing at least 1 severe exacerbation during benralizumab treatment.
Severe exacerbation incidence rate during benralizumab treatment, calculated as the number of patients with at least one exacerbation occurred during benralizumab treatment (cases) divided by the person-time at risk considering the duration of observation while the patient was receiving benralizumab.
Annual severe exacerbation rate, which will be calculated as the ratio between the total number of severe exacerbations occurred in the sample and the total number of person-years (i.e. the actual time-at-risk that all evaluable patients contributed to the study while they were in treatment with benralizumab).
at 16 weeks
Secondary ICS and OCS change during benralizumab treatment ICS dose change of any extent Change of OCS dose (final dose* with respect to index date; if applicable) at 16 weeks
Secondary IgE and eosinophils count during benralizumab treatment, and changes over time with respect to benralizumab treatment start Descriptive statistics of total IgE and eosinophils count in peripheral blood as measured at the time points specified.
Descriptive statistics of intra-patient changes over time in total IgE and eosinophils count in peripheral blood, at each time points specified with respect to index date (according to data availability).
at 16 weeks
Secondary lung function parameters during benralizumab treatment, and changes over time with respect to benralizumab treatment start Descriptive statistics of lung function parameters as measured at the time points specified.
Descriptive statistics of intra-patient changes over time in lung function parameters, at each time points specified with respect to index date (according to data availability).
at 16 weeks
Secondary patients' asthma control level and quality of life at benralizumab treatment start, during the observation period, and changes over time with respect to benralizumab treatment start Descriptive statistics of Asthma Control Test (ACT) total score at index date (if available).
Descriptive statistics of ACT total score at the time points specified in chapter 4.2 (according to data availability), along with proportion of patients with well-controlled asthma (i.e. ACT score major of 20).
Descriptive statistics of intra-patient changes in ACT total score, at each time points specified in chapter 4.2 with respect to index date (according to data availability).
Descriptive statistics of Asthma Quality of Life Questionnaire (AQLQ) total score at index date (if available).
Descriptive statistics of AQLQ total score at the time points specified in chapter 4.2 (according to data availability).
Descriptive statistics of intra-patient changes in AQLQ total score, at each time points specified in chapter 4.2 with respect to index date (according to data availability).
at 16 weeks
Secondary patient's adherence to benralizumab treatment Descriptive statistics of level of patient's adherence to benralizumab treatment, computed as the ratio (in percentage) between the number of actual injections received during the observation period over the number of expected injections (which will be estimated considering the injection schedulation specified in the SmPC). at 16 weeks
Secondary healthcare resource utilization during benralizumab treatment Descriptive statistics of total number (per patient) of the following healthcare resource utilization occurred during benralizumab treatment: GP/specialist visits for asthma, ER admissions for asthma, and hospitalizations for asthma. at 16 weeks
Secondary benralizumab discontinuation Proportion of patients with benralizumab permanent discontinuation during the observation period, and description of reasons. at 16 weeks
Secondary biologic treatments during the observation period Proportion of patients with subsequent biologic treatments for asthma, and description of type of treatment and reason for switch at 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Recruiting NCT04914078 - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4

External Links